on SANOFI-AVENTIS (EPA:SAN)
Sanofi's Sarclisa SC Approved in Japan for Multiple Myeloma
Sanofi has announced that the Ministry of Health in Japan has approved Sarclisa's subcutaneous (SC) formulation for multiple myeloma (MM) patients. This decision is based on multiple studies, including the pivotal IRAKLIA phase 3 study, which demonstrated non-inferior efficacy compared to intravenous administration.
Sarclisa SC will be available in combination therapies, such as with pomalidomide and dexamethasone, for relapsed or refractory mm, and with bortezomib, lenalidomide, and dexamethasone for newly diagnosed cases. The approval is significant for Japan, where MM diagnoses are increasing.
A regulatory submission for the CirCLIQ on-body injector, allowing an innovative delivery method for Sarclisa, is also under review in Japan. If approved, it would be the first anticancer treatment to employ this method in the country.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SANOFI-AVENTIS news